ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1135

Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
Abstract Number: 1136

Efficacy And Safety of Guselkumab Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results of the Galaxi 2 & 3 Phase 3 Studies
Abstract Number: 1137

Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)
Abstract Number: 1138

Association Between Long-Term Exposure to Fine Particles and Its Components and the Onset of Systemic Autoimmune Rheumatic Diseases in Quebec
Abstract Number: 1139

Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes
Abstract Number: 1140

Pulmonary Hypertension in Hospitalized Patients with Dermatomyositis & Polymyositis: A Nationwide Cohort Analysis
Abstract Number: 1141

Defining a Novel Type of Myositis: Immune Mediated Megaconial Myopathy (IMMM)
Abstract Number: 1142

Disease Trajectory in anti-MDA5 Dermatomyositis Patients Presented with Different Stage of Interstitial Lung Disease
Abstract Number: 1143

Epidemiology and Spectrum of Idiopathic Inflammatory Myopathies in Individuals of Sub-Saharan Ancestry: Data from the Tertiary Care Center of the Caribbean Island of Martinique
Abstract Number: 1144

Autoantibody and Radiological Profiles as Prognostic Indicators in Idiopathic Inflammatory Myopathies: Insights into Mortality and Interstitial Lung Disease Development
Abstract Number: 1145

Clinico-Immunological Profile and Treatment Outcomes of Clinically Significant Diaphragmatic Weakness in Patients with Idiopathic Inflammatory Myopathies: Results from the Largest Single-Center Cohort of 16 Cases
Abstract Number: 1146

Impact of COVID-19 on Myositis Testing Trends
Abstract Number: 1147

Evaluation of Adverse Pregnancy Outcomes in Patients with Inflammatory Myopathies and Ro Positivity
Abstract Number: 1148

Simplified Cutaneous Dermatomyositis Disease Area and Severity Index Activity Scores for Cutaneous Dermatomyositis
Abstract Number: 1149

Cause-Specific Proportionate Mortality Trends in Idiopathic Inflammatory Myopathies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].